Please login to the form below

Not currently logged in
Email:
Password:

Pan

This page shows the latest Pan news and features for those working in and with pharma, biotech and healthcare.

Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies

Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies

Whilst Keytruda was the first therapy to be approved for pan-tumour use in 2017, its Microsatellite Instability-High or Mismatch Repair-Deficient indication differs from the NTRK TA therapies.

Latest news

More from news
Approximately 6 fully matching, plus 229 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 30 partially matching documents found.

Latest appointments

More from appointments
Approximately 11 fully matching, plus 32 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 32 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...
Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...